Patents by Inventor Michael A. Gimbrone

Michael A. Gimbrone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7163808
    Abstract: Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: January 16, 2007
    Assignees: California Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone, Jr., Hai U. Wang
  • Patent number: 6759210
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: July 6, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Publication number: 20040081992
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: September 3, 2003
    Publication date: April 29, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone
  • Publication number: 20030188327
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: July 2, 2002
    Publication date: October 2, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone
  • Publication number: 20030097668
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, advanced atherosclerosis/plaque rupture, ischemia/reperfusion, hypertension, restenosis, cardiac calcification, allo/xenograft valvular calcifications, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: February 8, 2002
    Publication date: May 22, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Katherine Galvin, Dean A. Falb, Michael J. Donovan, Dennis Huszar, Michael A. Gimbrone
  • Patent number: 6534641
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: March 18, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6492126
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: December 10, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Publication number: 20020178458
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: November 9, 2001
    Publication date: November 28, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone
  • Publication number: 20020170077
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: October 5, 2001
    Publication date: November 14, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone
  • Publication number: 20020142441
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: August 7, 2001
    Publication date: October 3, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone
  • Publication number: 20020136726
    Abstract: Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g.
    Type: Application
    Filed: November 20, 2001
    Publication date: September 26, 2002
    Applicant: California Institute of Technology
    Inventors: David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone, Hai U. Wang
  • Publication number: 20020034736
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: June 6, 1997
    Publication date: March 21, 2002
    Inventors: DEAN A. FALB, Michael A. Gimbrone
  • Patent number: 6359194
    Abstract: The present invention is based on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-&bgr; signaling pathways. Such transgenic mice may be used for screening compounds that may potentially useful for treating or preventing cardiovascular disease.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: March 19, 2002
    Assignees: Millennium Pharmaceuticals, Inc., Brigham & Women's Hospital
    Inventors: Katherine Galvin, Dean A. Falb, Michael J. Donovan, Dennis Huszar, Michael A. Gimbrone, Jr.
  • Patent number: 6225084
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: May 1, 2001
    Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6221628
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: April 24, 2001
    Assignees: Brigham & Women's Hospital, Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6124433
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: September 26, 2000
    Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6087477
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: July 11, 2000
    Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6054558
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: April 25, 2000
    Assignees: Millennium Pharmaceuticals, Inc., Brigham and Womens's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6020463
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: February 1, 2000
    Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
  • Patent number: 6018025
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: January 25, 2000
    Assignees: Millenium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.